AbbVie Inc.·4

Feb 23, 5:00 PM ET

SALEKI-GERHARDT AZITA 4

4 · AbbVie Inc. · Filed Feb 23, 2024

Insider Transaction Report

Form 4
Period: 2024-02-21
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
Transactions
  • Exercise/Conversion

    Option (Right to Buy)

    2024-02-21$58.88/sh52,870$3,112,9860 total
    Exercise: $58.88From: 2016-02-19Exp: 2025-02-18Common Stock (52,870 underlying)
  • Exercise/Conversion

    Common Stock, $0.01 par value

    2024-02-21$58.88/sh+52,870$3,112,986296,814 total
  • Sale

    Common Stock, $0.01 par value

    2024-02-21$173.71/sh52,870$9,184,048243,944 total
Holdings
  • Common Stock, $0.01 par value

    (indirect: By Spouse)
    3,873
  • Common Stock, $0.01 par value

    (indirect: By Trust)
    2,322
Footnotes (4)
  • [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.51 to $174.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]Balance in AbbVie Savings program as of January 31, 2024.
  • [F3]The reporting person disclaims beneficial ownership of all securities held by her spouse.
  • [F4]Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Documents

1 file
  • 4
    form4-02232024_050201.xmlPrimary